polycarbophil (OTC)

Brand and Other Names:FiberCon, Fiber Lax, more...Equalactin, FiberNorm, Mitrolan
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablet

  • 625mg

tablet, chewable

  • 625mg

Constipation

1250 mg with 8 oz of water PO qday to q6hr; not to exceed 6 g/day

Dosage Forms & Strengths

tablet

  • 625mg

tablet, chewable

  • 625mg

Constipation

<6 years: Administer under physician supervision; 625 mg with 8 oz of water PO qDay or q12hr; not to exceed 1.25 g/day

>6-12 years: Swallow 1 tab qDay or q6hr

>12 years: 1250 mg with 8 oz of water PO q6hr; not to exceed 6 g/day

Constipation

1250 mg with 8 oz of water PO qday to q6hr; not to exceed 6 g/day

Next:

Interactions

Interaction Checker

and polycarbophil

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (5)

                • demeclocycline

                  polycarbophil decreases levels of demeclocycline by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                • doxycycline

                  polycarbophil decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                • minocycline

                  polycarbophil decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                • oxytetracycline

                  polycarbophil decreases levels of oxytetracycline by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                • tetracycline

                  polycarbophil decreases levels of tetracycline by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                Minor (1)

                • sodium picosulfate

                  polycarbophil decreases effects of sodium picosulfate by Mechanism: unspecified interaction mechanism. Minor/Significance Unknown.

                Previous
                Next:

                Adverse Effects

                Frequency Not Defined

                Abdominal fullness

                Flatulence

                Vomiting

                Stomach cramps

                Previous
                Next:

                Warnings

                Contraindications

                Hypersensitivity

                Bowel obstruction, appendicitis, dysphagia, fecal impaction, rectal bleeding

                Cautions

                Should be taken with enough fluid

                If tetracycline is concurrently administered, take tetracycline 1 hr after or 2 hr before polycarbophil

                Use in children <6 years

                Previous
                Next:

                Pregnancy & Lactation

                Pregnancy Category: NA; not absorbed; safe to be administered in pregnancy

                Lactation: No data in nursing women; not absorbed and should be safe to use in nursing women

                Pregnancy Categories

                A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                NA: Information not available.

                Previous
                Next:

                Pharmacology

                Mechanism of Action

                Bulk producing laxative that restores normal moisture level

                Pharmacokinetics

                Absorption: Minimal systemic absorption

                Onset: 12-72 hr

                Metabolism: Metabolically inert

                Excretion: Feces

                Previous
                Next:

                Images

                No images available for this drug.
                Previous
                Next:

                Patient Handout

                A Patient Handout is not currently available for this monograph.
                Previous
                Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.